a
2022
Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial
DE VLAM, Kurt, Peter TAYLOR, Philip J. MEASE, Paul PELOSO, Dieter WETZEL et. al.
Original name
Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial
Authors
DE VLAM, Kurt, Peter TAYLOR, Philip J. MEASE, Paul PELOSO, Dieter WETZEL, Nicolai BRUN, Brian WIENS, Jan BRANDT-JUERGENS, Edit DRESCHER, Eva DOKOUPILOVÁ (203 Czech Republic, belonging to the institution), Anna ROWINSKA-OSUCH, Nadia Abdel-Kader MARTIN and Frank BEHRENS
V originále
PsA is a chronic, inflammatory disease with multiple manifestations, with arthritis and skin involvement. Other areas of inflammation include enthesitis, dactylitis and nail involvement. Unresolved enthesitis leads to chronic pain and reduced quality of life1. IL-17 inhibitors have demonstrated benefits across multiple disease features. Izokibep is a unique IL-17A inhibitor with high potency (0.3 pM), small size (18.6 kD) and half-life extending albumin binding. The purpose is to assess the efficacy of izokibep 40 mg Q2W and 80 mg Q2W versus placebo on measures of enthesitis (most common being Leeds Enthesitis Index (LEI), as well as SPARCC), dactylitis and nails, and explore how these disease features impact quality of life (PsAID questionnaire) over 16 weeks. Drug safety was evaluated.